

AstraZeneca CFO Talks Tariffs, Forward Guidance, Earnings
Apr 30, 2025
Discover how AstraZeneca, as Britain's largest listed company, is navigating the challenges of potential trade wars and its impact on drug development. Dive into the concerning decline in MMR vaccination rates and its public health implications. Learn about the company’s innovative approaches to manufacturing, balancing siloed production with global supply chains. Lastly, explore the funding gap in pharmaceutical innovation between the US and Europe, and how UK policies influence investment in the sector.
AI Snips
Chapters
Transcript
Episode notes
Complex Pharma Supply Chains
- Pharma manufacturing involves complex supply chains requiring FDA approval and quality control.
- Shifting supply chains is time-intensive and can't be done quickly like a simple relocation.
AstraZeneca's Diverse Manufacturing Footprint
- AstraZeneca manufactures most of its US-sold products domestically, with 11 of 31 sites in the US.
- Minority imports from Europe require dual supply sources and potential rebalancing if tariffs arise.
Need for European Pharma Investment
- Europe needs more investment in pharma innovation to ensure health sovereignty and timely patient access.
- Increased R&D and manufacturing investments are crucial but rely on policy and budget decisions.